WO2007076534A1 - Method for modifying gut flora in animals - Google Patents

Method for modifying gut flora in animals Download PDF

Info

Publication number
WO2007076534A1
WO2007076534A1 PCT/US2006/062702 US2006062702W WO2007076534A1 WO 2007076534 A1 WO2007076534 A1 WO 2007076534A1 US 2006062702 W US2006062702 W US 2006062702W WO 2007076534 A1 WO2007076534 A1 WO 2007076534A1
Authority
WO
WIPO (PCT)
Prior art keywords
animal
amount
composition
food
vitamin
Prior art date
Application number
PCT/US2006/062702
Other languages
French (fr)
Inventor
Christina Khoo
Original Assignee
Hill's Pet Nutrition, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37951841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007076534(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT06846849T priority Critical patent/ATE541469T1/en
Priority to EP06846849.5A priority patent/EP1978821B2/en
Priority to JP2008548864A priority patent/JP2009522311A/en
Priority to CA002635038A priority patent/CA2635038A1/en
Priority to ES06846849T priority patent/ES2379824T3/en
Application filed by Hill's Pet Nutrition, Inc. filed Critical Hill's Pet Nutrition, Inc.
Priority to DK06846849.5T priority patent/DK1978821T3/en
Priority to BRPI0620734-0A priority patent/BRPI0620734A2/en
Priority to CN200680049706.0A priority patent/CN101351124B/en
Priority to AU2006330421A priority patent/AU2006330421B2/en
Publication of WO2007076534A1 publication Critical patent/WO2007076534A1/en
Priority to ZA2008/05413A priority patent/ZA200805413B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/10Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/163Sugars; Polysaccharides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/174Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/179Colouring agents, e.g. pigmenting or dyeing agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/25Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • A23L33/155Vitamins A or D
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

  • the present invention relates to methods for modifying the bacterial flora of the gastrointestinal tract (gut), and in some cases reducing gastrointestinal inflammation, in animals, more particularly animals having inflammatory bowel disease (IBD) or at risk for IBD.
  • the methods involve dietary intervention; accordingly the invention further relates to food compositions useful in practicing such methods.
  • the invention still further relates to kits and communicating means useful in practicing the invention.
  • the enhancement attributable to the method is associated with reduction of inflammation.
  • the method further comprises administering to the animal at least one of a probiotic and a prebiotic.
  • the invention also provides use of at least one antioxidant in the preparation of a composition for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD.
  • a food composition comprising, on a dry matter basis, at least one of: a. vitamin E in an amount of about 50 to about 1000 ⁇ g/g: b. vitamin C in an amount of about 30 to about 400 ⁇ g/g; and c. ⁇ -carotene in an amount of about 0.1 to about 5 ⁇ g/g: and further comprising at least one of a probiotic and a prebiotic.
  • a kit comprising ( I ) a composition comprising at least one antioxidant, and (2) at least one of: a. a probiotic: b. a prebiotic: c. a base food; d. an anti-lBD agent: and e. instructions for administering the antioxidant-containing composition and optionally other components of the kit to an animal having or at risk for IBD. to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract.
  • the means comprises one or more of a document, a digital storage medium, an optical storage medium, an audio presentation and a visual display containing the information and/or instructions.
  • a method of the invention is for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD.
  • the method comprises administering to the animal a composition comprising at least one antioxidant.
  • the gut flora i.e.. the community of bacteria resident in the gastrointestinal tract, comprises both beneficial and deleterious bacterial types or species. Whether a particular member of the gut flora is beneficial, deleterious or inconsequential to the health of the animal in particular circumstances can depend on a number of factors, but lor the purposes of the present invention certain types or species of bacteria can be considered beneficial and others deleterious.
  • beneficial members of the gut flora include bifidobacteria (species of the genus Bifidobacterium) and lactic acid bacteria, more particularly species of the genus Lactobacillus. Deleterious bacteria include pathogenic bacteria.
  • Examples of deleterious members of the gut flora include Clostridium spp.. Desulfovibrio spp. (including without limitation D. desulfuricans. D. intestinalis and D. vulgaris). Helicobacter spp. (including without limitation H. bizzozeronii, H. felis. H. heilmannii. H. pylori and H. salomonis) and pathogenic forms of Escherichia coli.
  • Gastrointestinal health typically depends on maintenance of an appropriate balance of beneficial and deleterious bacteria.
  • An increase in the population of deleterious bacteria and/or a decrease in the population of beneficial bacteria can be associated with a decline in gastrointestinal health.
  • an increase in the population of beneficial bacteria and/or a decrease in the population of deleterious bacteria can be associated with an improvement in gastrointestinal health, for example restoration of health or remission in an animal having a gastrointestinal disorder such as IBD, or prevention of onset of disease in an animal at risk for such a disorder.
  • the term "'associated with” in the present context does not necessarily imply a causal relationship, thus the balance of beneficial and deleterious bacteria can be implicated in pathogenesis or can be merely symptomatic of a gastrointestinal disorder.
  • “Enhancing” or “enhancement” of the balance herein means shifting the balance in favor of beneficial bacteria, and thus can involve an increase in beneficial bacteria and/or a decrease in deleterious bacteria.
  • enhancement of the balance arises from both a reduction in deleterious, e.g.. pathogenic, bacteria and an increase in beneficial bacteria.
  • Bacterial populations in the gut flora can be estimated by any procedure known in the art.
  • stool samples can be cultured using traditional plating methodologies, or illustratively by the fluorescence in situ hybridization (FISH) technique.
  • FISH fluorescence in situ hybridization
  • the subject animal according to the present method is one "having or at risk for IBD/ '
  • An animal having IBD is an animal in which any one of a spectrum of inflammatory gastrointestinal diseases and disorders recognized as a form of IBD has been professionally diagnosed or an animal exhibiting symptoms consistent with such diagnosis.
  • diseases and disorders include without limitation irritable bowel syndrome (IBS), ulcerative colitis and Crohn ' s disease.
  • An animal having chronic IBD but in remission at the time of application of the method is considered herein to be an animal '"having IBD.”
  • An animal at risk for IBD is an animal not having a history of IBD or exhibiting IBD symptoms but having one or more risk factors indicating a susceptibility to development of IBD.
  • risk factors can include genetic factors (e.g., a family history of IBD) and physiological factors (e.g.. elevated levels of one or more pro-inflammatory biomarkers and/or depressed levels of one or more anti-inflammatory biomarkers).
  • the animal can be human or non-human, including avian, bovine, canine, equine, feline, hircine. murine, ovine and porcine animals.
  • the animal is a companion animal such as a canine or feline, particularly a dog or a cat.
  • a composition comprising at least one antioxidant is administered to the animal. Administration can be by any suitable route, including oral or parenteral, but is typically oral.
  • the composition is a food that is orally administered. Such a food comprising at least one antioxidant can represent a substantial part of the diet of an animal.
  • At least one antioxidant can be present in a food or range of foods consumed daily by the animal and providing substantially complete nutrition of the animal.
  • at least one antioxidant can be administered as a nutritional supplement, or can be present in a snack, a treat or an at least partially edible toy given to the animal separately from its regular food.
  • Any nutritionally acceptable antioxidant can be used.
  • an antioxidant other than one having pharmacological properties as in the case of drugs such as 5-ASA or prodrugs thereof
  • an antioxidant other than a polyphenol is used, although a polyphenol antioxidant such as taxifolin can optionally be present in addition to a non-polyphenol antioxidant.
  • a variety of materials that exhibit free radical quenching or absorbing capacity can be used as antioxidants (for example, fruits, vegetables, certain vitamins, and other chemical compounds).
  • Raw ingredients with high oxygen radical absorbing content include, for example, raw spinach pomace, raw tomato pomace, raw citrus pulp, raw grape pomace, raw carrot granules, raw broccoli, raw green tea, raw corn gluten meal, and raw rice bran.
  • Foods or food products that exhibit free radical quenching or absorbing capacity include, for example, spinach (e.g., spinach pomace), tomato (e.g.. tomato pomace), citrus fruit (e.g.. citrus pulp), grape (e.g., grape pomace), carrot (e.g.. carrot granules), broccoli, corn gluten meal, and rice bran.
  • Compounds that exhibit free radical quenching or absorbing capacity include, for example, vitamin ⁇ . vitamin C, carotenoids. coenzyme Qio (ubiquinone), glutathione, L-carnitine, ⁇ -lipoic acid, N-acetylcysteine, S-adenosylmethionine, soy isoflavones and taurine.
  • the composition to be administered comprises one or more of vitamin E. vitamin C and a carotenoid.
  • vitamin E herein includes any form of vitamin E suitable for consumption by an animal including, but not limited to, any tocopherol or tocotrienol compound, any enantiomer or racemate thereof, and any mixture of such compounds having vitamin E activity. e.g.. ⁇ -tocopherol (5.7,8-trimethyltocoI), ⁇ -tocopherol (5,8-dimethyltocol). ⁇ -tocopherol (7.8-dimethyltocol). ⁇ -tocopherol (8-methyltocol). ⁇ -tocotrienol (5.7,8-trimethyltocotrienol). ⁇ -tocotrienol (5.8-dimethyltocotrienol).
  • Vitamin E can be administered as any one or a mixture of the above compounds or in the form of various derivatives thereof such as esters, including vitamin E acetate, succinate, palmitate and the like, that exhibit vitamin E activity after ingestion by an animal.
  • vitamin E as used in the present method comprises ⁇ -tocopherol or an ester thereof.
  • Vitamin E amounts can be expressed in international units (IU) wherein 1 IU is an amount of vitamin E having vitamin E activity equivalent to 1 mg DL- ⁇ -tocopheryl acetate. Alternatively, vitamin E amounts can be expressed as total tocopherol.
  • vitamin C herein includes any form of vitamin C suitable for consumption by an animal including, but not limited to. ascorbic acid, L-ascorbic acid, and various derivatives thereof such as calcium phosphate salt, cholesteryl salt, and ascorbate-2- monophosphate.
  • Salts of vitamin C include the sodium salt, calcium salt, zinc salt, and ferrous salt.
  • Esters include stearate, palmitate and like derivatives.
  • Vitamin C can be in any physical form such as a liquid, a semisolid, a solid, or a heat stable form that exhibits vitamin C activity after ingestion by a patient. Vitamin C amounts are expressed herein as ascorbic acid.
  • the term '"carotenoid” herein includes any form of a carotenoid suitable for consumption by an animal including, but not limited to, natural and synthetic carotenoids derived from orange -yellow pigment in plants, algae, leaves, roots, vegetation, tomato meal, red palm oil. tomato powder, and tomato pomace/pulp.
  • the carotenoid ⁇ -carotene is a precursor of vitamin A occurring naturally in plants.
  • the antioxidant activity of carotenoids is generally independent of any vitamin A activity they may possess as a result of metabolism to vitamin A by an animal. In this regard, it is noted that cats in particular are generally unable to convert ⁇ -carotene to vitamin A.
  • Other carotenoids include astaxanthine. ⁇ -carotene, cryptoxanthin, lutein, Iycopene and zeaxanthin.
  • Suitable amounts of one or more antioxidants for administration herein can be expressed in relation to the amount of food (typically expressed on a dry matter basis) consumed by the animal.
  • the antioxidant-containing composition can be administered in an amount providing one or more of: a. vitamin E in a total tocopherol amount of about 50 to about 1000 ⁇ g. for example about 100 to about 800 ⁇ g, or about 200 to about 600 ⁇ g; b. vitamin C in an amount of about 30 to about 400 ⁇ g, for example about 50 to about 200 ⁇ g. or about 75 to about 150 ⁇ g: and c. carotenoid. e.g.. ⁇ -carotene. in an amount of about 0.1 to about 5 ⁇ g. for example about 0.2 to about 2 ⁇ g, or about 0.5 to about 1.5 ⁇ g: per gram of food, on a dry matter basis, consumed.
  • the composition to be administered according to the present method is a food forming a substantial part of an animal ' s diet
  • the food should typically comprise, on a dry matter basis, one or more of: a. vitamin E in a total tocopherol amount of about 50 Io about 1000 ⁇ g/g, for example about 100 to about 800 ⁇ g/g. or about 200 to about 600 ⁇ g/g; b. vitamin C in an amount of about 30 to about 400 ⁇ g/g. for example about 50 to about 200 ⁇ g/g. or about 75 to about 150 ⁇ g/g; and c. carotenoid. e.g., ⁇ -carotcne, in an amount of about 0.1 to about 5 ⁇ g/g. for example about 0.2 to about 2 ⁇ g/g. or about 0.5 to about 1 .5 ⁇ g/g.
  • all three of vitamin E, vitamin C and carotenoid e.g., ⁇ -carotene are present, illustratively in amounts as indicated above.
  • compositions comprising vitamin E, vitamin C and/or a carotenoid are other than a food forming a substantial part of the animal's diet, it should typically be administered in an amount consistent with that set forth above, in relation to the amount of food consumed by the animal.
  • a supplement a snack, a treat or an at least partially edible toy.
  • the composition contains higher concentrations of antioxidant(s) than set forth above, as the total amount of such compositions consumed is substantially lower than in the case of a food forming a substantial part of the diet.
  • vitamin E enriched in vitamin E.
  • ⁇ -carotene can enhance the balance of beneficial and deleterious bacteria in an animal's gut flora by comparison ⁇ vith a comparative food having lower levels of these antioxidants.
  • the enhancement involves both an increase in the population of beneficial bacteria and a decrease in the population of deleterious bacteria.
  • the enhancement of gut flora balance attributable to practice of the method is associated with reduction of inflammation, more particularly reduction of gastrointestinal inflammation, such as inflammation of the colonic mucosa.
  • Reduction of inflammation may be directly observable, for example by colonoscopy, or may be evidenced by a decrease in one or more pro-inflammatory biomarkers and/or an increase in one or more anti-inflammatory biomarkers in a biofluid or tissue of the animal.
  • pro-inflammatory biomarkers that may be decreased in blood serum include C-reactive protein (CRP). oxidized glutathione (GSSG). alkenals, serum amyloid A (SAA) and tumor necrosis factor alpha (TNF- ⁇ .
  • cytokine a pro-inflammatory cytokine
  • anti-inflammatory biomarkers include reduced glutathione (GSH). oxygen radical absorbing capacity (ORAC), and the anti-inflammatory cytokines transforming growth factor beta (TGF- ⁇ ) and interleukin 10 (IL-IO).
  • GSH glutathione
  • ORAC oxygen radical absorbing capacity
  • TGF- ⁇ transforming growth factor beta
  • IL-IO interleukin 10
  • a method of the invention comprises, in addition to administration of a composition comprising an antioxidant, administration of one or more of a probiotic and a prebiotic.
  • a probiotic is a preparation or composition comprising viable microbes, for example bacteria, molds or yeasts.
  • Probiotics of interest herein comprise at least one kind of beneficial bacteria, for example bifidobacteria and/or lactic acid bacteria.
  • a probiotic useful herein comprises beneficial bacteria comprising one or more of Bifidobacterium spp. and Lactobacillus spp.
  • Suitable species include, without limitation. Bifidobacterium animalis (including B. animalis subsp. lactis. sometimes referred to as B. lactis).
  • Bifidobacterium thermophilum Lactobacillus acidophilus. Lactobacillus animalis, Lactobacillus casei, Lactobacillus plantarum. Lactobacillus reuteri. and Lactobacillus rhamnosus.
  • a probiotic can be included in the same composition as the antioxidant, for example in a food composition, or it can be administered separately.
  • a suitable amount of a probiotic is generally about 10 6 to about IO 12 cfu (colony forming units) per gram of food on a dry matter basis consumed by the animal.
  • a probiotic can enhance the balance of the gut flora simply by acting as an inoculum for an increased population of beneficial bacteria, and/or by antagonizing growth of deleterious bacteria. In some situations co-action of the antioxidant and a probiotic can occur, and this may under some circumstances lead to a synergistic interaction of the antioxidant and the probiotic. although such synergism is not a requirement herein.
  • a prebiotic is a nondigestible substance that preferentially stimulates growth of beneficial bacteria.
  • Most prebiotics are fermentable carbohydrates; examples include oligosaccharides, galactans and ⁇ -glucans. obtainable from various plant and microbial sources. Specific examples include arabinogalactan. fructooligosaccharide (FOS) and inulin. a polysaccharide that yields FOS.
  • the prebiotic can be administered separately from or in the same composition, e.g., a food composition, as the antioxidant.
  • a method of the invention comprises administering an anti-lBD agent, in addition to a composition comprising an antioxidant, and optionally a probiotic and/or a prebiotic.
  • An "anti-IBD agent” herein is a pharmacological agent, typically a drug or herbal preparation, providing therapeutic benefit to an IBD patient, for example in reducing inflammation, alleviating symptoms such as pain and/or diarrhea, etc. Suitable examples include, without limitation, steroids such as beclomethasone, budesonide. prednisolone, prednisone and tixocortol; 5-ASA releasing preparations such as mesalamine.
  • the anti-IBD agent can be administered by any suitable route, including oral, parenteral, transdermal and rectal routes. If desired, an anti-IBD agent suitable for oral administration can be included in the same composition as the antioxidant.
  • an aspect of the invention is use of at least one antioxidant in preparation of a composition for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD. All embodiments described or enumerated above for a method of the invention apply equally to such use.
  • the invention provides, in yet another embodiment, a food composition, useful for example in practice of a method as described herein.
  • a food composition of the present embodiment typically has a content of metabolizable energy and nutrients that render it suitable as a substantial part of the diet of an animal.
  • the composition comprises, on a dry matter basis. ( 1 ) at least one of: a. vitamin E in a total tocopherol amount of about 50 to about 1000 ⁇ g/g.
  • vitamin C in an amount of about 30 to about 400 ⁇ g/g, for example about 50 to about 200 ⁇ g/g, or about 75 to about 150 ⁇ g/g: and c. carotenoid. e.g., ⁇ -carotene. in an amount of about 0.1 to about 5 ⁇ g/g. for example about 0.2 to about 2 ⁇ g/g, or about 0.5 to about 1.5 ⁇ g/g; and (2) at least one of a probiotic and a prebiotic.
  • the composition comprises a probiotic comprising beneficial bacteria of one or more of Bifidobacterium spp. and Lactobacillus spp.
  • a suitable amount of probiotic is typically about 10 f) to about 10 12 cfu/g. on a dry matter basis.
  • the composition comprises a prebiotic comprising one or more of an oligosaccharide, a galactan or a ⁇ -glucan.
  • the food composition generally contains amounts and a balance of nutrients appropriate to the animal for which it is intended.
  • the composition is a pet food, for example a food nutritionally and/or organoleptically adapted for feeding to a companion animal such as a canine or feline.
  • a kit of the invention comprises (I) a composition comprising at least one antioxidant, and (2) at least one of: a. a probiotic; b. a prebiotic; c. a base food; d. an anti-lBD agent: and e. instructions for administering the antioxidant-containing composition and optionally other components of the kit to an animal having or at risk for IBD, to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract.
  • kits can be co-packaged, for example provided in separate containers within a single outer package or otherwise bundled together.
  • components of the kit can be separately packaged but made available (e.g.. sold, offered for sale or marketed) in such a way that a consumer can obtain all necessary components. This can be accomplished by means, for example, of "virtual packaging' * , wherein instructions in a medium separate from physical components of the kit relate to use of the physical kit components.
  • the medium for the instructions can be. but are not limited to, print, radio or television broadcast, website or visual display, for example at a point of sale.
  • the kit comprises a base food, a composition comprising at least one antioxidant, and one or more of a probiotic and a prebiotic.
  • the base food contains amounts and a balance of nutrients appropriate to the animal for which it is intended but contains a low level of antioxidants, generally insufficient to provide enhancement of the balance of beneficial and deleterious bacteria in the gastrointestinal tract.
  • the antioxidant- containing composition acts as a supplement, for addition to or admixture with the base food, to provide an antioxidant enriched food capable of providing the desired enhancement.
  • a probiotic and/or a prebiotic, if included in the kit can be present in the supplement, or in the base food, or in a separate container.
  • the kit of this embodiment optionally further comprises instructions for addition or admixture of the supplement to the base food and/or information about the benefits of such addition or admixture.
  • the means comprises one or more of a document, a digital storage medium, an optical storage medium, an audio presentation and a visual display containing the information and/or instructions.
  • the means can comprise a displayed web site, a brochure, a product label, a package insert, an advertisement or a visual display.
  • a study is conducted with 1 1 healthy (not having IBD) cats and 1 1 cats diagnosed with IBD.
  • a standard canned feline pet food with or without antioxidant enrichment (see analysis in Table I) is fed to the cats for 2 weeks, followed by crossover to the other food, which is fed for a further 2 weeks.
  • Example 1 A study is conducted with 1 1 healthy cats and 1 1 cats diagnosed with IBD. Each of the same control (non-enriched) and test (antioxidant-enriched) foods as in Example 1 is fed to the cats for 4 weeks, followed by crossover to the other food, which is fed for a further 4 weeks. Stool (fecal) samples are collected at the beginning and end of each 4-week feeding period and are submitted for bacterial culture using traditional plating methodology. Counts for two kinds of deleterious bacteria (Clostridia and E. coli) and two kinds of beneficial bacteria (lactic acid bacteria and bifidobacteria) are obtained. Results are shown in Table 4.
  • E. coli population is about 3 log units (about one thousand times) higher in samples from cats with IBD than in samples from healthy cats.
  • Cats fed the antioxidant-enriched food exhibit a decline of about 0.8 to about 1 log unit in E. coli population by comparison with the control food.
  • the antioxidant-enriched food also tend to lower Clostridium populations, although this effect is more marked in healthy cats than in cats with IBD.
  • populations of beneficial bacteria both lactic acid bacteria and bifidobacteria
  • an antioxidant-enriched diet to animals with IBD can enhance the balance of beneficial and deleterious bacteria in the gut flora.
  • Such enhancement can be further assisted, for example by supplementing an antioxidant-enriched food with one or more probiotics comprising beneficial bacteria such as Lactobacillus spp. or Bifidobacterium spp.

Abstract

A method for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for inflammatory bowel disease (IBD) by administering to the animal a composition comprising at least one antioxidant, optionally in conjunction with one or more of a probiotic and a prebiotic.

Description

METHOD FOR MODIFYING GUT FLORA IN ANIMALS
BACKGROUND OF THE INVENTION
Field of the Invention
[0001] The present invention relates to methods for modifying the bacterial flora of the gastrointestinal tract (gut), and in some cases reducing gastrointestinal inflammation, in animals, more particularly animals having inflammatory bowel disease (IBD) or at risk for IBD. In certain embodiments the methods involve dietary intervention; accordingly the invention further relates to food compositions useful in practicing such methods. The invention still further relates to kits and communicating means useful in practicing the invention.
Description of the Related Art
[0002] IBD has been associated with changes in gut flora; however, as concluded in a review paper by Marteau et al. (2004), Aliment. Pharmacol. Ther. 20(Suppl. 4): 18-23. this is a difficult subject and there is need for more research. Various studies reviewed in the Marteau paper have indicated effects on IBD of modifying bacterial flora by administration of probiotics.
[0003] Kruis (2004), Aliment. Pharmacol. Ther. 20(Suppl. 4):75-78 reviewed clinical studies of therapeutic effects of probiotics in IBD. It was reported that some studies showed convincing therapeutic benefit, but others did not.
[0004] In another review paper by Jergens (1999), Veterinary Clinics of North America: Small Animal Practice 29(2):501— 521. it was stated that "evidence of a role for bacterial microflora in canine/feline IBD is presently lacking." Jergens documented dietary therapy for IBD. focusing on hypoallergenic diets, adjusted omega-6 to omega-3 fatty acid ratio and fiber supplementation.
[0005] Fernandez-Banares et al. (1989). Amer. J. Gastroenterol. 84(7):744-748 reported that human patients with IBD had lower blood plasma levels of certain vitamins, including vitamin C and β-caroteπe, but not vitamin E, than healthy controls. [0006] BufFinton & Doe (1995), Free Radical Biology & Medicine 19(6):91 1-918 reported decreased antioxidant defenses in patients with IBD and noted that the antiinflammatory drug 5-aminosalicyIic acid (5-ASA), extensively used in IBD therapy, for example in the form of its prodrug sulfasalazine, has potent antioxidant capacity. Preliminary trials of antioxidant therapy were cited and said to "encourage further exploration of antioxidant strategies for the treatment of IBD.'' [0007] Lih-Brody et al. (1996). Digestive Diseases & Sciences 4 l ( l 0):2078-2086 reported a study of reactive oxygen intermediates (ROIs) in the colonic mucosa of IBD patients, and stated that an imbalance in formation of ROIs and antioxidant microniitrients
'may provide a rationale for therapeutic modulation with antioxidants."'
[0008] D'Odorico et al. (2001). Scand. J. Gastroenterol. 36(12): 1289-1294 reported reduced antioxidant (including vitamin E and β-carotene) concentration in plasma of IBD patients by comparison with controls and concluded that antioxidant depletion is likely to be important in the pathophysiology of IBD.
|00091 Gonzalez et al. (2001). Int. J. Vitam. Nutr. Res. 71(4):243-250 reported that vitamin E supplementation in a rat model protected the colon from oxidative stress associated with inflammation.
[0010] There remains a need in the art for new methods of modifying gut flora, especially adjusting the balance of beneficial and deleterious (e.g., pathogenic) bacteria in the gut in favor of beneficial species, in animals having IBD or at risk for IBD.
SUMMARY OF THE INVENTION
[0011 ] There is now provided a method for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD comprising administering to the animal a composition comprising at least one antioxidant, for example vitamin E, vitamin C and/or a carotenoid.
[0012] In some embodiments, the enhancement attributable to the method is associated with reduction of inflammation.
[0013] Optionally, the method further comprises administering to the animal at least one of a probiotic and a prebiotic.
[0014] The invention also provides use of at least one antioxidant in the preparation of a composition for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD.
[0015] There is also provided a food composition comprising, on a dry matter basis, at least one of: a. vitamin E in an amount of about 50 to about 1000 μg/g: b. vitamin C in an amount of about 30 to about 400 μg/g; and c. β-carotene in an amount of about 0.1 to about 5 μg/g: and further comprising at least one of a probiotic and a prebiotic. [0016] There is still further provided a kit comprising ( I ) a composition comprising at least one antioxidant, and (2) at least one of: a. a probiotic: b. a prebiotic: c. a base food; d. an anti-lBD agent: and e. instructions for administering the antioxidant-containing composition and optionally other components of the kit to an animal having or at risk for IBD. to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract.
[0017] There is still further provided a means for communicating information about and/or instructions for one or more of: a. administering a composition comprising at least one antioxidant, optionally in conjunction with one or more of (i) a probiotic, (H) a prebiotic, and (iii) an anti-IBD agent, to an animal having or at risk for IBD. to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of the animal; b. admixing a composition comprising at least one antioxidant with one or more of (i) a probiotic, (ii) a prebiotic, (iii) an anti-IBD agent and (iv) a base food, to provide a combination for administration to an animal having or at risk for IBD. to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of the animal; and c. using a kit to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD; wherein the means comprises one or more of a document, a digital storage medium, an optical storage medium, an audio presentation and a visual display containing the information and/or instructions.
DETAILED DESCRIPTION OF THE INVENTION
[0018] A method of the invention is for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD. The method comprises administering to the animal a composition comprising at least one antioxidant.
[0019] The gut flora, i.e.. the community of bacteria resident in the gastrointestinal tract, comprises both beneficial and deleterious bacterial types or species. Whether a particular member of the gut flora is beneficial, deleterious or inconsequential to the health of the animal in particular circumstances can depend on a number of factors, but lor the purposes of the present invention certain types or species of bacteria can be considered beneficial and others deleterious. Examples of beneficial members of the gut flora include bifidobacteria (species of the genus Bifidobacterium) and lactic acid bacteria, more particularly species of the genus Lactobacillus. Deleterious bacteria include pathogenic bacteria. Examples of deleterious members of the gut flora include Clostridium spp.. Desulfovibrio spp. (including without limitation D. desulfuricans. D. intestinalis and D. vulgaris). Helicobacter spp. (including without limitation H. bizzozeronii, H. felis. H. heilmannii. H. pylori and H. salomonis) and pathogenic forms of Escherichia coli.
[0020] Gastrointestinal health typically depends on maintenance of an appropriate balance of beneficial and deleterious bacteria. An increase in the population of deleterious bacteria and/or a decrease in the population of beneficial bacteria can be associated with a decline in gastrointestinal health. Conversely, an increase in the population of beneficial bacteria and/or a decrease in the population of deleterious bacteria can be associated with an improvement in gastrointestinal health, for example restoration of health or remission in an animal having a gastrointestinal disorder such as IBD, or prevention of onset of disease in an animal at risk for such a disorder. The term "'associated with" in the present context does not necessarily imply a causal relationship, thus the balance of beneficial and deleterious bacteria can be implicated in pathogenesis or can be merely symptomatic of a gastrointestinal disorder.
[0021 ] "Enhancing" or "enhancement" of the balance herein means shifting the balance in favor of beneficial bacteria, and thus can involve an increase in beneficial bacteria and/or a decrease in deleterious bacteria. In some embodiments of the invention, enhancement of the balance arises from both a reduction in deleterious, e.g.. pathogenic, bacteria and an increase in beneficial bacteria.
[0022] Bacterial populations in the gut flora can be estimated by any procedure known in the art. For example, stool samples can be cultured using traditional plating methodologies, or illustratively by the fluorescence in situ hybridization (FISH) technique. [0023] The subject animal according to the present method is one "having or at risk for IBD/' An animal having IBD is an animal in which any one of a spectrum of inflammatory gastrointestinal diseases and disorders recognized as a form of IBD has been professionally diagnosed or an animal exhibiting symptoms consistent with such diagnosis. Such diseases and disorders include without limitation irritable bowel syndrome (IBS), ulcerative colitis and Crohn's disease. An animal having chronic IBD but in remission at the time of application of the method is considered herein to be an animal '"having IBD." An animal at risk for IBD is an animal not having a history of IBD or exhibiting IBD symptoms but having one or more risk factors indicating a susceptibility to development of IBD. Such risk factors can include genetic factors (e.g., a family history of IBD) and physiological factors (e.g.. elevated levels of one or more pro-inflammatory biomarkers and/or depressed levels of one or more anti-inflammatory biomarkers).
[0024| The animal can be human or non-human, including avian, bovine, canine, equine, feline, hircine. murine, ovine and porcine animals. In some embodiments, the animal is a companion animal such as a canine or feline, particularly a dog or a cat. [0025| According to the present method, a composition comprising at least one antioxidant is administered to the animal. Administration can be by any suitable route, including oral or parenteral, but is typically oral. In some embodiments, the composition is a food that is orally administered. Such a food comprising at least one antioxidant can represent a substantial part of the diet of an animal. For example, at least one antioxidant can be present in a food or range of foods consumed daily by the animal and providing substantially complete nutrition of the animal. Alternatively or in addition, at least one antioxidant can be administered as a nutritional supplement, or can be present in a snack, a treat or an at least partially edible toy given to the animal separately from its regular food. [0026] Any nutritionally acceptable antioxidant can be used. In some embodiments, an antioxidant other than one having pharmacological properties (as in the case of drugs such as 5-ASA or prodrugs thereof) is used. In some embodiments, an antioxidant other than a polyphenol is used, although a polyphenol antioxidant such as taxifolin can optionally be present in addition to a non-polyphenol antioxidant. A variety of materials that exhibit free radical quenching or absorbing capacity can be used as antioxidants (for example, fruits, vegetables, certain vitamins, and other chemical compounds). Raw ingredients with high oxygen radical absorbing content include, for example, raw spinach pomace, raw tomato pomace, raw citrus pulp, raw grape pomace, raw carrot granules, raw broccoli, raw green tea, raw corn gluten meal, and raw rice bran. Foods or food products that exhibit free radical quenching or absorbing capacity include, for example, spinach (e.g., spinach pomace), tomato (e.g.. tomato pomace), citrus fruit (e.g.. citrus pulp), grape (e.g., grape pomace), carrot (e.g.. carrot granules), broccoli, corn gluten meal, and rice bran. Compounds that exhibit free radical quenching or absorbing capacity include, for example, vitamin Ε. vitamin C, carotenoids. coenzyme Qio (ubiquinone), glutathione, L-carnitine, α-lipoic acid, N-acetylcysteine, S-adenosylmethionine, soy isoflavones and taurine. [0027] In some embodiments, the composition to be administered comprises one or more of vitamin E. vitamin C and a carotenoid.
10028) The term "vitamin E" herein includes any form of vitamin E suitable for consumption by an animal including, but not limited to, any tocopherol or tocotrienol compound, any enantiomer or racemate thereof, and any mixture of such compounds having vitamin E activity. e.g.. α-tocopherol (5.7,8-trimethyltocoI), β-tocopherol (5,8-dimethyltocol). γ-tocopherol (7.8-dimethyltocol). δ-tocopherol (8-methyltocol). α-tocotrienol (5.7,8-trimethyltocotrienol). β-tocotrienol (5.8-dimethyltocotrienol). γ-tocotrienol (7.8-dimethyltocotrienol). and δ-tocotrienol (8-methyltocotrienol). Vitamin E can be administered as any one or a mixture of the above compounds or in the form of various derivatives thereof such as esters, including vitamin E acetate, succinate, palmitate and the like, that exhibit vitamin E activity after ingestion by an animal. Typically, vitamin E as used in the present method comprises α-tocopherol or an ester thereof. Vitamin E amounts can be expressed in international units (IU) wherein 1 IU is an amount of vitamin E having vitamin E activity equivalent to 1 mg DL-α-tocopheryl acetate. Alternatively, vitamin E amounts can be expressed as total tocopherol.
10029] The term "vitamin C" herein includes any form of vitamin C suitable for consumption by an animal including, but not limited to. ascorbic acid, L-ascorbic acid, and various derivatives thereof such as calcium phosphate salt, cholesteryl salt, and ascorbate-2- monophosphate. Salts of vitamin C include the sodium salt, calcium salt, zinc salt, and ferrous salt. Esters include stearate, palmitate and like derivatives. Vitamin C can be in any physical form such as a liquid, a semisolid, a solid, or a heat stable form that exhibits vitamin C activity after ingestion by a patient. Vitamin C amounts are expressed herein as ascorbic acid.
[0030] The term '"carotenoid" herein includes any form of a carotenoid suitable for consumption by an animal including, but not limited to, natural and synthetic carotenoids derived from orange -yellow pigment in plants, algae, leaves, roots, vegetation, tomato meal, red palm oil. tomato powder, and tomato pomace/pulp. The carotenoid β-carotene is a precursor of vitamin A occurring naturally in plants. The antioxidant activity of carotenoids is generally independent of any vitamin A activity they may possess as a result of metabolism to vitamin A by an animal. In this regard, it is noted that cats in particular are generally unable to convert β-carotene to vitamin A. Other carotenoids include astaxanthine. α-carotene, cryptoxanthin, lutein, Iycopene and zeaxanthin.
10031] Suitable amounts of one or more antioxidants for administration herein can be expressed in relation to the amount of food (typically expressed on a dry matter basis) consumed by the animal. Illustratively, the antioxidant-containing composition can be administered in an amount providing one or more of: a. vitamin E in a total tocopherol amount of about 50 to about 1000 μg. for example about 100 to about 800 μg, or about 200 to about 600 μg; b. vitamin C in an amount of about 30 to about 400 μg, for example about 50 to about 200 μg. or about 75 to about 150 μg: and c. carotenoid. e.g.. β-carotene. in an amount of about 0.1 to about 5 μg. for example about 0.2 to about 2 μg, or about 0.5 to about 1.5 μg: per gram of food, on a dry matter basis, consumed.
[0032] Where the composition to be administered according to the present method is a food forming a substantial part of an animal's diet, the food should typically comprise, on a dry matter basis, one or more of: a. vitamin E in a total tocopherol amount of about 50 Io about 1000 μg/g, for example about 100 to about 800 μg/g. or about 200 to about 600 μg/g; b. vitamin C in an amount of about 30 to about 400 μg/g. for example about 50 to about 200 μg/g. or about 75 to about 150 μg/g; and c. carotenoid. e.g., β-carotcne, in an amount of about 0.1 to about 5 μg/g. for example about 0.2 to about 2 μg/g. or about 0.5 to about 1 .5 μg/g.
|0033] In one embodiment, all three of vitamin E, vitamin C and carotenoid (e.g., β-carotene) are present, illustratively in amounts as indicated above.
[0034] Where a composition comprising vitamin E, vitamin C and/or a carotenoid is other than a food forming a substantial part of the animal's diet, it should typically be administered in an amount consistent with that set forth above, in relation to the amount of food consumed by the animal. Typically, in the case of a supplement, a snack, a treat or an at least partially edible toy. the composition contains higher concentrations of antioxidant(s) than set forth above, as the total amount of such compositions consumed is substantially lower than in the case of a food forming a substantial part of the diet.
[0035] In accordance with the invention, it has surprisingly been found that administration of a food enriched in vitamin E. vitamin C and β-carotene can enhance the balance of beneficial and deleterious bacteria in an animal's gut flora by comparison λvith a comparative food having lower levels of these antioxidants. In some cases the enhancement involves both an increase in the population of beneficial bacteria and a decrease in the population of deleterious bacteria.
[0036J In some embodiments of the invention, the enhancement of gut flora balance attributable to practice of the method is associated with reduction of inflammation, more particularly reduction of gastrointestinal inflammation, such as inflammation of the colonic mucosa. Reduction of inflammation may be directly observable, for example by colonoscopy, or may be evidenced by a decrease in one or more pro-inflammatory biomarkers and/or an increase in one or more anti-inflammatory biomarkers in a biofluid or tissue of the animal. Examples of pro-inflammatory biomarkers that may be decreased in blood serum include C-reactive protein (CRP). oxidized glutathione (GSSG). alkenals, serum amyloid A (SAA) and tumor necrosis factor alpha (TNF-α. a pro-inflammatory cytokine). Examples of anti-inflammatory biomarkers that may be increased in blood serum include reduced glutathione (GSH). oxygen radical absorbing capacity (ORAC), and the anti-inflammatory cytokines transforming growth factor beta (TGF-β) and interleukin 10 (IL-IO).
[0037] Optionally, a method of the invention comprises, in addition to administration of a composition comprising an antioxidant, administration of one or more of a probiotic and a prebiotic.
[0038J A probiotic is a preparation or composition comprising viable microbes, for example bacteria, molds or yeasts. Probiotics of interest herein comprise at least one kind of beneficial bacteria, for example bifidobacteria and/or lactic acid bacteria. In one embodiment a probiotic useful herein comprises beneficial bacteria comprising one or more of Bifidobacterium spp. and Lactobacillus spp. Suitable species include, without limitation. Bifidobacterium animalis (including B. animalis subsp. lactis. sometimes referred to as B. lactis). Bifidobacterium longum (including B. infantis). Bifidobacterium thermophilum. Lactobacillus acidophilus. Lactobacillus animalis, Lactobacillus casei, Lactobacillus plantarum. Lactobacillus reuteri. and Lactobacillus rhamnosus.
[0039] A probiotic can be included in the same composition as the antioxidant, for example in a food composition, or it can be administered separately. A suitable amount of a probiotic is generally about 106 to about IO12 cfu (colony forming units) per gram of food on a dry matter basis consumed by the animal. [0040] In combination with the antioxidant, a probiotic can enhance the balance of the gut flora simply by acting as an inoculum for an increased population of beneficial bacteria, and/or by antagonizing growth of deleterious bacteria. In some situations co-action of the antioxidant and a probiotic can occur, and this may under some circumstances lead to a synergistic interaction of the antioxidant and the probiotic. although such synergism is not a requirement herein.
[0041] A prebiotic is a nondigestible substance that preferentially stimulates growth of beneficial bacteria. Most prebiotics are fermentable carbohydrates; examples include oligosaccharides, galactans and β-glucans. obtainable from various plant and microbial sources. Specific examples include arabinogalactan. fructooligosaccharide (FOS) and inulin. a polysaccharide that yields FOS. The prebiotic can be administered separately from or in the same composition, e.g., a food composition, as the antioxidant.
[0042] In yet another embodiment, a method of the invention comprises administering an anti-lBD agent, in addition to a composition comprising an antioxidant, and optionally a probiotic and/or a prebiotic. An "anti-IBD agent" herein is a pharmacological agent, typically a drug or herbal preparation, providing therapeutic benefit to an IBD patient, for example in reducing inflammation, alleviating symptoms such as pain and/or diarrhea, etc. Suitable examples include, without limitation, steroids such as beclomethasone, budesonide. prednisolone, prednisone and tixocortol; 5-ASA releasing preparations such as mesalamine. olsalazine and sulfasalazine; metronidazole: azathioprine: etc. The anti-IBD agent can be administered by any suitable route, including oral, parenteral, transdermal and rectal routes. If desired, an anti-IBD agent suitable for oral administration can be included in the same composition as the antioxidant.
[0043] Also an aspect of the invention is use of at least one antioxidant in preparation of a composition for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD. All embodiments described or enumerated above for a method of the invention apply equally to such use. [0044] The invention provides, in yet another embodiment, a food composition, useful for example in practice of a method as described herein. A food composition of the present embodiment typically has a content of metabolizable energy and nutrients that render it suitable as a substantial part of the diet of an animal. The composition comprises, on a dry matter basis. ( 1 ) at least one of: a. vitamin E in a total tocopherol amount of about 50 to about 1000 μg/g. for example about 100 to about 800 μg/g. or about 200 to about 600 μg/g: b. vitamin C in an amount of about 30 to about 400 μg/g, for example about 50 to about 200 μg/g, or about 75 to about 150 μg/g: and c. carotenoid. e.g., β-carotene. in an amount of about 0.1 to about 5 μg/g. for example about 0.2 to about 2 μg/g, or about 0.5 to about 1.5 μg/g; and (2) at least one of a probiotic and a prebiotic.
[0045] In an illustrative embodiment, the composition comprises a probiotic comprising beneficial bacteria of one or more of Bifidobacterium spp. and Lactobacillus spp. A suitable amount of probiotic is typically about 10f) to about 1012 cfu/g. on a dry matter basis.
[0046| In another illustrative embodiment, the composition comprises a prebiotic comprising one or more of an oligosaccharide, a galactan or a β-glucan.
[0047] The food composition generally contains amounts and a balance of nutrients appropriate to the animal for which it is intended. In one embodiment the composition is a pet food, for example a food nutritionally and/or organoleptically adapted for feeding to a companion animal such as a canine or feline.
[0048] A kit of the invention comprises (I) a composition comprising at least one antioxidant, and (2) at least one of: a. a probiotic; b. a prebiotic; c. a base food; d. an anti-lBD agent: and e. instructions for administering the antioxidant-containing composition and optionally other components of the kit to an animal having or at risk for IBD, to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract.
[0049] Components of the kit can be co-packaged, for example provided in separate containers within a single outer package or otherwise bundled together. Alternatively, components of the kit can be separately packaged but made available (e.g.. sold, offered for sale or marketed) in such a way that a consumer can obtain all necessary components. This can be accomplished by means, for example, of "virtual packaging'*, wherein instructions in a medium separate from physical components of the kit relate to use of the physical kit components. The medium for the instructions can be. but are not limited to, print, radio or television broadcast, website or visual display, for example at a point of sale. [0050] In one embodiment, the kit comprises a base food, a composition comprising at least one antioxidant, and one or more of a probiotic and a prebiotic. The base food contains amounts and a balance of nutrients appropriate to the animal for which it is intended but contains a low level of antioxidants, generally insufficient to provide enhancement of the balance of beneficial and deleterious bacteria in the gastrointestinal tract. The antioxidant- containing composition acts as a supplement, for addition to or admixture with the base food, to provide an antioxidant enriched food capable of providing the desired enhancement. A probiotic and/or a prebiotic, if included in the kit, can be present in the supplement, or in the base food, or in a separate container. The kit of this embodiment optionally further comprises instructions for addition or admixture of the supplement to the base food and/or information about the benefits of such addition or admixture.
[0051] In a still further embodiment, there is provided a means for communicating information about and/or instructions for one or more of: a. administering a composition comprising at least one antioxidant, optionally in conjunction with one or more of (i) a probiotic, (ii) a prebiotic, and (iii) an anti-lBD agent, to an animal having or al risk for IBD, to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of the animal; b. admixing a composition comprising at least one antioxidant with one or more of (i) a probiotic. (ii) a prebiotic, (iii) an anti-lBD agent and (iv) a base food, to provide a combination for administration to an animal having or at risk for IBD, to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of the animal; and c. using a kit of the present invention to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD; wherein the means comprises one or more of a document, a digital storage medium, an optical storage medium, an audio presentation and a visual display containing the information and/or instructions. Illustratively, the means can comprise a displayed web site, a brochure, a product label, a package insert, an advertisement or a visual display. {0052] The invention is not limited to the particular methodology, protocols, and reagents described herein because they may vary. Further, the terminology' used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention. As used herein and in the appended claims, the singular forms "a," '"an," and "'the" include plural reference unless the context clearly dictates otherwise. Similarly, the words "comprise", "comprises", and "'comprising'' are to be interpreted inclusively rather than exclusively.
[0053] Unless defined otherwise, all technical and scientific terms and any acronyms used herein have the same meanings as commonly understood by one of ordinary skill in the art in the field of the invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred methods, devices, and materials are described herein.
[0054] All patents, patent applications, and publications mentioned herein are incorporated herein by reference to the extent allowed by law for the purpose of describing and disclosing the compounds, processes, techniques, procedures, technology, articles, and other compositions and methods disclosed therein that might be used with the present invention. However, nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
EXAMPLES
[0055] The invention can be further illustrated by the following examples of preferred embodiments thereof, although it will be understood that these examples are included merely for purposes of illustration and are not intended to limit the scope of the invention unless otherwise specifically indicated.
Example 1
[0056] A study is conducted with 1 1 healthy (not having IBD) cats and 1 1 cats diagnosed with IBD. A standard canned feline pet food with or without antioxidant enrichment (see analysis in Table I) is fed to the cats for 2 weeks, followed by crossover to the other food, which is fed for a further 2 weeks.
Table 1 Analysis of Non-enriched (control) and Enriched (test) Foods (DM = Dry Matter)
Figure imgf000013_0001
Figure imgf000014_0001
[0057| At the end of each 2-week feeding period, blood samples are taken from each cat. Serum levels of reduced and oxidized glutathione (GSH and GSSG respectively) as antioxidant biomarkers are measured. Mean levels are shown in Table 2. Also. T lymphocyte proliferation levels in response to non-specific mitogens concanavalin A (ConA) and pokeweed mitogen (PWM) are measured as biomarkers of inflammatory response. Mean response levels are shown in Table 3.
Table 2 GSII and GSSG Levels in Scrum of Cats on Control and Test Foods
Figure imgf000014_0002
Table 3 T Lymphocyte Proliferation Response to Mitogens ConA and PWM
Figure imgf000014_0003
[0058] As shown in Table 2. feeding the antioxidant-enriched food results in higher GSH levels in both healthy cats and cats with IBD. When fed the control (non-enriched) food, the GSH level in cats with IBD is lower than that in healthy cats: feeding the antioxidant- enriched food raises the GSH level in cats with IBD to a level comparable to that of healthy cats on the control food.
[0059] As shown in Table 3. feeding the antioxidant-enriched food to cats with IBD brings T lymphocyte proliferation response to a level closer to that observed in healthy cats. However, this response is not completely normalized (did not become equal to that in healthy cats).
Example 2
[0060] A study is conducted with 1 1 healthy cats and 1 1 cats diagnosed with IBD. Each of the same control (non-enriched) and test (antioxidant-enriched) foods as in Example 1 is fed to the cats for 4 weeks, followed by crossover to the other food, which is fed for a further 4 weeks. Stool (fecal) samples are collected at the beginning and end of each 4-week feeding period and are submitted for bacterial culture using traditional plating methodology. Counts for two kinds of deleterious bacteria (Clostridia and E. coli) and two kinds of beneficial bacteria (lactic acid bacteria and bifidobacteria) are obtained. Results are shown in Table 4.
Table 4 Logl O cfu/g Feces by Traditional Plating Methodology
Figure imgf000015_0001
(0061 ] As shown in Table 4, E. coli population is about 3 log units (about one thousand times) higher in samples from cats with IBD than in samples from healthy cats. Cats fed the antioxidant-enriched food exhibit a decline of about 0.8 to about 1 log unit in E. coli population by comparison with the control food. The antioxidant-enriched food also tend to lower Clostridium populations, although this effect is more marked in healthy cats than in cats with IBD. Meanwhile, populations of beneficial bacteria (both lactic acid bacteria and bifidobacteria) are increased in cats with IBD fed the antioxidant-enriched food by comparison with those fed the control food. In healthy cats only the bifidobacteria show an increase in response to the antioxidant-enriched food in this study.
|0062] It can be concluded from this study that administration of an antioxidant-enriched diet to animals with IBD can enhance the balance of beneficial and deleterious bacteria in the gut flora. Such enhancement can be further assisted, for example by supplementing an antioxidant-enriched food with one or more probiotics comprising beneficial bacteria such as Lactobacillus spp. or Bifidobacterium spp.
[0063] In the specification, there have been disclosed typical preferred embodiments of the invention and, although specific terms are employed, they are used in a generic and descriptive sense only and not for purposes of limitation, the scope of the invention being set forth in the claims. Obviously many modifications and variations of the invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims the invention may be practiced otherwise than as specifically described.

Claims

What is claimed is:
1. A method for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for inflammatory bowel disease (IBD) comprising administering to the animal a composition comprising at least one antioxidant.
2. The method of Claim 1 wherein the enhancement comprises an increase in level of beneficial bacteria and a decrease in level of deleterious bacteria.
3. The method of Claim 2 wherein the beneficial bacteria comprise one or more of Lactobacillus spp. and Bifidobacterium spp.
4. The method of Claim 2 wherein the deleterious bacteria comprise one or more of Clostridium spp., Desulfovibrio spp., Helicobacter spp. and pathogenic forms of Escherichia coli.
5. The method of Claim 1 wherein the enhancement is associated with reduction of inflammation.
6. The method of Claim 5 wherein the reduction of inflammation is evidenced by a decrease in a pro-inflammatory biomarker and/or an increase in an anti-inflammatory biomarker in a biofluid or tissue of the animal.
7. The method of Claim 6 wherein at least one of serum CRP. oxidized glutathione, alkenals, amyloid and TNF-α is decreased and/or at least one of serum reduced glutathione, ORACs, TGF-β and IL-10 is increased.
8. The method of Claim 1 wherein the antioxidant comprises one or more of vitamin E. vitamin C and a carotenoid.
9. The method of Claim 8 wherein the composition is administered in an amount providing at least one of: a. vitamin E in a total tocopherol amount of about 50 to about 1000 μg; b. vitamin C in an amount of about 30 to about 400 μg: and c. β-carotene in an amount of about 0.1 to about 5 μg: per gram of food on a dry matter basis consumed by the animal.
10. The method of Claim 8 wherein the composition is administered in an amount providing at least one of: a. vitamin E in a total tocopherol amount of about 100 to about 800 μg; b. vitamin C in an amount of about 50 to about 200 μg; and c. β-carotene in an amount of about 0.2 to about 2 μg; per gram of food on a dry matter basis consumed by the animal.
1 1. The method of Claim 1 further comprising administering to the animal at least one of a probiotic and a prcbiotic.
12. The method of Claim 1 1 wherein a probiotic is administered comprising beneficial bacteria comprising one or more of Bifidobacterium spp. and Lactobacillus spp.
13. The method of Claim 12 wherein the probiotic is administered in an amount of about 106 to about 1012 cfu per gram of food on a dry matter basis consumed by the animal.
14. The method of Claim 1 1 wherein a prebiotic is administered comprising one or more of an oligosaccharide, a galactan or a β-glucan.
15. The method of Claim 1 wherein the composition is a food, a supplement, a snack, a treat, or an at least partially edible toy.
16. The method of Claim 1 wherein the composition is a food administered orally as a part of the diet of the animal.
17. The method of Claim 16 wherein the food comprises, on a dry matter basis, al least one of: a. vitamin E in a total tocopherol amount of about 50 to about 1000 μg/g; b. vitamin C in an amount of about 30 to about 400 μg/g; and c. β-carotene in an amount of about 0.1 to about 5 μg/g.
18. The method of Claim 16 wherein the food comprises, on a dry matter basis, at least one of: a. vitamin E in a total tocopherol amount of about 100 to about 800 μg/gi b. vitamin C in an amount of about 50 to about 200 μg/g; and c. β-carotene in an amount of about 0.2 to about 2 μg/g.
19. The method of Claim 16 wherein the food further comprises at least one of a probiotic and a prebiotic.
20. The method of Claim 19 wherein a probiotic is present in the food comprising beneficial bacteria comprising one or more of Bifidobacterium spp. and Lactobacillus spp.
21. The method of Claim 19 wherein a probiotic is present in the food in an amount, on a dry matter basis, of about 106 to about 1012 cfu/g.
22. The method of Claim 19 wherein a prebiotic comprising one or more of an oligosaccharide, a galactan or a β-glucan is present in the food.
23. The method of Claim 1 wherein the composition is administered in conjunction with administration of one or more anti-IBD agents.
24. The method of Claim 1 wherein the animal is canine or feline.
25. Use of at least one antioxidant in preparation of a composition for enhancing the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD.
26. A food composition comprising., on a dry matter basis, at least one of: a. vitamin E in a total tocopherol amount of about 50 to about 1000 μg/g; b. vitamin C in an amount of about 30 to about 400 μg/g: and c. β-carotene in an amount of about 0.1 to about 5 μg/g; and further comprising at least one of a probiotic and a prebiotic.
27. The composition of Claim 26 comprising, on a dry matter basis, at least one of: a. vitamin E in a total tocopherol amount of about 100 to about 800 μg/g; b. vitamin C in an amount of about 50 to about 200 μg/g: and c. β-carotene in an amount of about 0.2 to about 2 μg/g.
28. The composition of Claim 26 comprising a probiotic that comprises beneficial bacteria comprising one or more of Bifidobacterium spp. and Lactobacillus spp.
29. The composition of Claim 26 comprising a probiotic in an amount, on a dry matter basis, of about 10δ to about 1012 cfu/g.
30. The composition of Claim 26 comprising a prebiotic that comprises one or more of an oligosaccharide, a galactan or a β-g!ucan.
31. The composition of Claim 26 that is a canine or feline pet food.
32. A kit comprising (1 ) a composition comprising at least one antioxidant, and (2) at least one of: a. a probiotic; b. a prebiotic; c. a base food: d. an anti-IBD agent; and e. instructions for administering the antioxidant-contatning composition and optionally other components of the kit to an animal having or at risk for IBD. to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract.
33. A means for communicating information about and/or instructions for one or more of: a. administering a composition comprising at least one antioxidant, optionally in conjunction with one or more of (i) a probiotic. (ii) a prebiotic and (iii) an anti- IBD agent, to an animal having or at risk for IBD, to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of the animal; b. admixing a composition comprising at least one antioxidant with one or more of (i) a probiotic, (ii) a prebiotic. (iii) an anti-IBD agent and (iv) a base food, to provide a combination for administration to an animal having or at risk for IBD, to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of the animal: and c. using the kit of Claim 32 to enhance the balance of beneficial and deleterious bacteria in the gastrointestinal tract of an animal having or at risk for IBD: wherein the means comprises one or more of a document, a digital storage medium, an optical storage medium, an audio presentation and a visual display containing the information and/or instructions.
34. The means of Claim 33 comprising a displayed web site, a brochure, a product label, a package insert, an advertisement, or a visual display.
PCT/US2006/062702 2005-12-29 2006-12-29 Method for modifying gut flora in animals WO2007076534A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2006330421A AU2006330421B2 (en) 2005-12-29 2006-12-29 Method for modifying gut flora in animals
EP06846849.5A EP1978821B2 (en) 2005-12-29 2006-12-29 Method for modifying gut flora in animals
JP2008548864A JP2009522311A (en) 2005-12-29 2006-12-29 Methods for regulating intestinal flora in animals
CA002635038A CA2635038A1 (en) 2005-12-29 2006-12-29 Method for modifying gut flora in animals
ES06846849T ES2379824T3 (en) 2005-12-29 2006-12-29 Method to modify the intestinal flora in animals
AT06846849T ATE541469T1 (en) 2005-12-29 2006-12-29 METHOD FOR MODIFYING THE INTESTINAL FLORA IN ANIMALS
DK06846849.5T DK1978821T3 (en) 2005-12-29 2006-12-29 Method of Modifying Intestinal Flora in Animals
BRPI0620734-0A BRPI0620734A2 (en) 2005-12-29 2006-12-29 method for improving the balance of beneficial and harmful bacteria in an animal's gastrointestinal tract, use of at least one antioxidant, feed composition, kit, and means for communicating information and / or instructions
CN200680049706.0A CN101351124B (en) 2005-12-29 2006-12-29 Method for modifying gut flora in animals
ZA2008/05413A ZA200805413B (en) 2005-12-29 2008-06-20 Method for modifying gut flora in animals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75480705P 2005-12-29 2005-12-29
US60/754,807 2005-12-29

Publications (1)

Publication Number Publication Date
WO2007076534A1 true WO2007076534A1 (en) 2007-07-05

Family

ID=37951841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/062702 WO2007076534A1 (en) 2005-12-29 2006-12-29 Method for modifying gut flora in animals

Country Status (13)

Country Link
US (1) US20070178078A1 (en)
EP (1) EP1978821B2 (en)
JP (1) JP2009522311A (en)
CN (1) CN101351124B (en)
AT (1) ATE541469T1 (en)
AU (1) AU2006330421B2 (en)
BR (1) BRPI0620734A2 (en)
CA (1) CA2635038A1 (en)
DK (1) DK1978821T3 (en)
ES (1) ES2379824T3 (en)
RU (1) RU2426451C2 (en)
WO (1) WO2007076534A1 (en)
ZA (1) ZA200805413B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063221A2 (en) * 2007-11-13 2009-05-22 Biotec Pharmacon Asa Methods of treating or preventing inflammatory diseases of the intestinal tract
WO2011018547A1 (en) 2009-08-12 2011-02-17 Vetcare Oy Probiotic preparation for the prevention or treatment of canine gastrointestinal disorders
EP2332426A1 (en) * 2009-12-11 2011-06-15 Technische Universität Graz Prebiotic
EP2514429A1 (en) * 2009-10-21 2012-10-24 Obshestvo S Ogranichennoj Otvetstvennostju "PARAFARM" Antioxidant
CN103636945A (en) * 2013-12-06 2014-03-19 江苏威泰龙生物科技有限公司 Compound type biological active peptide product for livestock and poultry and application thereof
EP3235506A1 (en) 2010-07-26 2017-10-25 Qu Biologics Inc Immunogenic anti-inflammatory compositions
WO2018183941A2 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2019150004A1 (en) 2018-02-05 2019-08-08 Vetcare Oy Health beneficial composition comprising lactobacillus and method for the preparation thereof
RU2706953C1 (en) * 2015-12-30 2019-11-21 Хиллс Пет Нутришн, Инк. Controlled release pet food compositions for delivering a polyphenol source
WO2021020992A1 (en) * 2019-08-01 2021-02-04 Общество с ограниченной ответственностью "Гелеспон" Method for purging the intestine and kit for implementing same
EP4252629A2 (en) 2016-12-07 2023-10-04 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
PL1885383T3 (en) 2005-05-31 2017-06-30 Iams Europe B.V. Feline probiotic bifidobacteria
WO2006130187A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic lactobacilli
JP5799299B2 (en) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーThe Iams Company Method for reducing inflammation and stress in mammals using glucose antimetabolite, avocado or avocado extract
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US10212954B2 (en) * 2009-12-18 2019-02-26 Colgate-Palmolive Company Pet food compositions including probiotics and methods of manufacture and use thereof
US9629881B2 (en) 2010-02-01 2017-04-25 Rebiotix, Inc. Bacteriotherapy for clostridium difficile colitis
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CA2914636C (en) 2013-06-05 2021-04-06 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CN114990099A (en) 2015-05-11 2022-09-02 迈彼欧提克斯制药有限公司 System and method for growing probiotic biofilm on solid particulates for colonizing bacteria in the intestinal tract
PL3307289T3 (en) 2015-06-09 2022-01-17 Rebiotix, Inc. Methods of manufacture of microbiota restoration therapy (mrt) compositions
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
EP3463403A4 (en) 2016-05-25 2020-04-15 Mybiotics Pharma Ltd Composition and methods for microbiota therapy
WO2018013871A1 (en) * 2016-07-13 2018-01-18 Kaleido Biosciences, Inc. Glycan compositions and methods of use
US10842809B2 (en) * 2016-12-16 2020-11-24 Hills Pet Nutrition, Inc. Pet food compositions
PT3716958T (en) * 2017-11-28 2023-12-07 Dermapharm Ag Composition for the treatment of dysbiosis of the intestinal microbiota
CN110193030A (en) * 2019-04-29 2019-09-03 山东苏柯汉生物工程股份有限公司 A kind of dog probiotics and preparation method thereof
WO2022090254A1 (en) * 2020-10-28 2022-05-05 Dsm Ip Assets B.V. Direct delivery of vitamins to inhibit microbial pathogens

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780451A (en) * 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
WO2003071883A1 (en) * 2002-02-28 2003-09-04 Centro Sperimentale Del Latte S.P.A. Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations
US20050124576A1 (en) * 2003-12-05 2005-06-09 Hill's Pet Nutrition, Inc. Composition and method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262799T1 (en) * 1996-01-31 2004-04-15 Univ South Alabama FOOD AND VITAMIN PRODUCTIONS WITH NATURAL ISOMERS OF REDUCED FOLATES
JP3390613B2 (en) * 1996-10-04 2003-03-24 明治乳業株式会社 Bifidus factor activity enhancer / stabilizer
JPH10168095A (en) 1996-12-10 1998-06-23 Cci Corp Preventing and therapeutic agent for inflammatory intestinal disease
NZ527924A (en) 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
US20030198661A1 (en) * 2000-01-31 2003-10-23 Mars Incorporated Antioxidant compositions and methods for companion animals
US6238708B1 (en) * 1999-02-23 2001-05-29 The Iams Company Composition and process for controlling glucose metabolism in companion animals by dietary starch
AU2001278432B2 (en) * 2000-05-25 2007-08-30 Societe Des Produits Nestle S.A. Novel probiotics for pet food applications
GB0027761D0 (en) 2000-11-14 2000-12-27 Nestle Sa Nutritional composition for an immune condition
JP4853986B2 (en) * 2001-09-20 2012-01-11 雪印メグミルク株式会社 Preventive and therapeutic agent for inflammatory bowel disease and irritable bowel syndrome
AU2003245156A1 (en) 2002-06-21 2004-01-06 Canacure Corporation Liquid compositions comprising non-digestible oligosaccharides and green tea catechins, method and uses thereof
US20050107465A1 (en) 2003-10-01 2005-05-19 Papas Andreas M. Composition for treating inflammatory bowel disease
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty Compositions and methods of treatment for inflammatory diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780451A (en) * 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
WO2003071883A1 (en) * 2002-02-28 2003-09-04 Centro Sperimentale Del Latte S.P.A. Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations
US20050124576A1 (en) * 2003-12-05 2005-06-09 Hill's Pet Nutrition, Inc. Composition and method

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063221A3 (en) * 2007-11-13 2009-07-02 Biotec Pharmacon Asa Methods of treating or preventing inflammatory diseases of the intestinal tract
WO2009063221A2 (en) * 2007-11-13 2009-05-22 Biotec Pharmacon Asa Methods of treating or preventing inflammatory diseases of the intestinal tract
WO2011018547A1 (en) 2009-08-12 2011-02-17 Vetcare Oy Probiotic preparation for the prevention or treatment of canine gastrointestinal disorders
US9095160B2 (en) 2009-08-12 2015-08-04 Vetcare Oy Probiotic preparation for the prevention or treatment of canine gastrointestinal disorders
EP2514429A4 (en) * 2009-10-21 2013-07-24 Obshestvo S Ogranichennoj Otvetstvennostju Parafarm Antioxidant
EP2514429A1 (en) * 2009-10-21 2012-10-24 Obshestvo S Ogranichennoj Otvetstvennostju "PARAFARM" Antioxidant
WO2011070010A1 (en) * 2009-12-11 2011-06-16 Technische Universität Graz Prebiotic
EP2332426A1 (en) * 2009-12-11 2011-06-15 Technische Universität Graz Prebiotic
EP3235506A1 (en) 2010-07-26 2017-10-25 Qu Biologics Inc Immunogenic anti-inflammatory compositions
EP4324526A2 (en) 2010-07-26 2024-02-21 Qu Biologics Inc. Immunogenic anti-inflammatory compositions
CN103636945A (en) * 2013-12-06 2014-03-19 江苏威泰龙生物科技有限公司 Compound type biological active peptide product for livestock and poultry and application thereof
RU2706953C1 (en) * 2015-12-30 2019-11-21 Хиллс Пет Нутришн, Инк. Controlled release pet food compositions for delivering a polyphenol source
RU2740439C2 (en) * 2015-12-30 2021-01-14 Хиллс Пет Нутришн, Инк. Fodder compositions for domestic animals
EP4252629A2 (en) 2016-12-07 2023-10-04 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183941A2 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2019150004A1 (en) 2018-02-05 2019-08-08 Vetcare Oy Health beneficial composition comprising lactobacillus and method for the preparation thereof
WO2021020992A1 (en) * 2019-08-01 2021-02-04 Общество с ограниченной ответственностью "Гелеспон" Method for purging the intestine and kit for implementing same

Also Published As

Publication number Publication date
RU2426451C2 (en) 2011-08-20
CN101351124A (en) 2009-01-21
AU2006330421A1 (en) 2007-07-05
RU2008131072A (en) 2010-02-10
AU2006330421B2 (en) 2011-03-24
US20070178078A1 (en) 2007-08-02
ZA200805413B (en) 2013-03-27
EP1978821B1 (en) 2012-01-18
BRPI0620734A2 (en) 2012-09-18
ATE541469T1 (en) 2012-02-15
CN101351124B (en) 2014-09-03
CA2635038A1 (en) 2007-07-05
DK1978821T3 (en) 2012-05-14
EP1978821B2 (en) 2019-02-06
JP2009522311A (en) 2009-06-11
EP1978821A1 (en) 2008-10-15
ES2379824T3 (en) 2012-05-04

Similar Documents

Publication Publication Date Title
AU2006330421B2 (en) Method for modifying gut flora in animals
AU2011385194B2 (en) Compositions and methods for modifying gastrointestinal flora
JP6820868B2 (en) Compositions and methods for enhancing neurogenesis in animals
JP6301655B2 (en) Methods and compositions suitable for promoting healthy skin
JP2014501759A (en) Method and composition suitable for blood glucose control in animals
JP2011510684A (en) Compositions, methods, and kits for enhancing immune responses to respiratory conditions
US20090118229A1 (en) Carotenoid-containing compositions and methods
CN108289476B (en) Hydration of animals
JP5901618B2 (en) Method for increasing the production or activity of catalase
Mukhopadhya et al. The microbiological and immunomodulatory effects of spray-dried versus wet dietary supplementation of seaweed extract in the pig gastrointestinal tract
WO2013052433A2 (en) Methods and compositions for reducing food intake and body weight gain in animals
JP2023059641A (en) Composition for improving intestinal environment
Shoveller et al. Functional foods and companion animals.
Rutherfurd-Markwick et al. Functional foods and nutraceuticals for cats and dogs.
WO2014128737A1 (en) Dietary food for the treatment of inflammatory bowel diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680049706.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006330421

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2635038

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008548864

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006330421

Country of ref document: AU

Date of ref document: 20061229

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006846849

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008131072

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0620734

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080627